Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 02, 2023 -- Lyell Immunopharma, Inc. , a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid... | May 2, 2023